Novartis ($NVS) saw a setback on its meningitis vaccine Menveo earlier this month, when the FDA unexpectedly rejected a version designed for use in infants. But even if that version eventually gets the agency's blessing, it may not win key recommendations from the Centers for Disease Control and Prevention, thanks to already declining rates of the disease. Report